Cargando…
Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study
BACKGROUND: Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluat...
Autores principales: | van der Tol, Arjan, Van Biesen, Wim, Van Laecke, Steven, Bogaerts, Kris, De Lombaert, Koen, Warrinnier, Hans, Vanholder, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281099/ https://www.ncbi.nlm.nih.gov/pubmed/22359611 http://dx.doi.org/10.1371/journal.pone.0031639 |
Ejemplares similares
-
Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies
por: Vanholder, Raymond, et al.
Publicado: (2008) -
Towards a Rational Screening Strategy for Albuminuria: Results from the Unreferred Renal Insufficiency Trial
por: van der Tol, Arjan, et al.
Publicado: (2010) -
Novel non-cystic features of polycystic kidney disease: having new eyes or seeking new landscapes
por: Van Laecke, Steven, et al.
Publicado: (2020) -
Dose of dialysis in the intensive care unit: is the venom in the dose or in the clinical experience?
por: Lameire, Norbert, et al.
Publicado: (2009) -
What is new in uremic toxicity?
por: Vanholder, Raymond, et al.
Publicado: (2008)